Erratum: Why we can prevent, control and possibly treat - But will not eradicate-rabies (Future Virology (2015) 10:5 (517-535)DOI 10.2217/fvl.15.26);Why we can prevent, control and possibly treat - But will not eradicate - Rabies

Future Virology

Volumn 10, Issue 5, 2015, Pages 517-535

  Rupprecht, Charles E ^a,b   Kuzmin, Ivan V ^c  

^a WISTAR INSTITUTE   (United States)

^b LYSSA LLC   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

antiviral treatment; eradication; Lyssavirus; neglected viral infections; One Health; prophylaxis; rabies; vaccination; viral encephalitis; zoonosis

Indexed keywords

AFRICAN; ASIAN; BAT; CENTRAL AMERICAN; DEVELOPED COUNTRY; DISEASE ERADICATION; DISEASE TRANSMISSION; DOG; FATALITY; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; NONHUMAN; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RABIES; REVIEW; SOUTH AMERICAN; ZOONOSIS;

CANIS FAMILIARIS; LYSSAVIRUS;

EID: 84930335548     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.15.67     Document Type: Erratum

References (125)

1. World Health Organization. WHO Expert Consultation on Rabies: Second Report. WHO, Geneva, Switzerland (2013
2. Banyard AC, Evans JS, Luo TR, Fooks AR. Lyssaviruses and bats: emergence and zoonotic threat. Viruses 6, 2974-2990 (2014
3. Voloch CM, Capellao RT, Mello B, Schrago CG. Analysis of adaptive evolution in Lyssavirus genomes reveals pervasive diversifying selection during species diversification. Viruses 6, 4465-4478 (2014
4. Annand EJ, Reid PA. Clinical review of two fatal equine cases of infection with the insectivorous bat strain of Australian bat Lyssavirus. Aust. Vet. J. 92(9), 324-332 (2014
5. Horton DL, Banyard AC, Marston DA et al. Antigenic and genetic characterization of a divergent African virus, Ikoma Lyssavirus. J. Gen. Virol. 95(Pt 5), 1025-1032 (2014
6. Fischer M, Freuling C M, Muler T et al. Molecular double-check strategy for the identification and characterization of European Lyssaviruses. J. Virol. Methods 203, 23-32 (2014
7. Kgaladi J, Wright N, Coertse J et al. Diversity and epidemiology of Mokola virus. PLoS Negl. Trop. Dis. 7(10), e2511 (2013
8. McE lhinney LM, Marston DA, Leech S et al. Molecular epidemiology of bat Lyssaviruses in Europe. Zoonoses Public Health 60, 35-45 (2013
9. Liu Y, Li N, Zhang S et al. Analysis of the complete genome of the first Irkut virus isolate from China: comparison across the Lyssavirus genus. Mol. Phylogenet. Evol. 69(3), 687-693 (2013
10. Picard-Meyer E, Servat A, Robardet E, Moinet M, Borel C, Cliquet F. Isolation of Bokeloh bat Lyssavirus in Myotis nattereri in France. Arch. Virol. 158(11), 2333-2340 (2013
11. Arechiga Ceballos N, Vazquez MorÃn S, Berciano JM et al. Novel Lyssavirus in bat, Spain. Emerg. Infect. Dis. 19(5), 793-795 (2013
12. Koraka P, Martina BE, Roose JM et al. In vitro and in vivo isolatlon and characterization of Duvenhage virus. PLoS Pathog. 8(5), e1002682 (2012
13. Hayman DT, Fooks AR, Rowcliffe et al. Endemic Lagos bat virus infection in Eidolon helvum. Epidemiol. Infect. 140, 2163-2171 (2012
14. Rupprecht CE, Turmelle A, Kuzmin IV. A perspective on Lyssavirus emergence and perpetuation. Curr. Opin. Virol. 1(6), 662-670 (2011
15. Harkess G, Fooks AR. Lyssaviruses: special emphasis on rabies virus and other members of the Lyssavirus genus. Methods Mol. Biol. 665, 279-307 (2011
16. Kuzmin IV, Mayer AE, Niezgoda M et al. Shimoni bat virus, a new representative of the Lyssavirus genus. Virus Res. 149(2), 197-210 (2010
17. Evans JS, Horton DL, Easton AJ, Fooks AR, Banyard AC. Rabies virus vaccines: is there a need for a pan-Lyssavirus vaccine?. Vaccine 30(52), 7447-7454 (2012
18. Kuzmin IV, Novella IS, Dietzgen RG, Padhi A, Rupprecht CE. The rhabdoviruses: biodiversity, phylogenetics, and evolution. Infect. Genet. Evol. 9(4), 541-553 (2009
19. Gluska S, Zahavi EE, Chein M et al. Rabies virus hijacks and accelerates the p75NTR retrograde axonal transport machinery. PLoS Pathog. 10(8), e1004348 (2014
20. Koraka P, Bosch BJ, Cox M et al. A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice. Vaccine 32(36), 4644-4650 (2014
21. Fouquet B, Nikolic J, Larrous F et al. The focal adhesion kinase is involved in rabies virus infection through its interaction with the viral phosphoprotein P. J. Virol. 89(3), 1640-1651 (2015
22. Chai Q, She R, Huang Y, Fu ZF. Expression of neuronal CXCL10 induced by rabies virus infection initiates infiltration of inflammatory cells, production of chemokines/cytokines and enhancement of blood-brain barrier permeability. J. Virol. 89(1), 870-876 (2015
23. Barkhouse DA, Garcia SA, Bongiorno EK, Lebrun A, Faber M, Hooper DC. Expression of IFNy by a recombinant rabies virus strongly attenuates the pathogenicity of the virus via induction of type I interferon. J. Virol. 89(1) 312-322 (2015
24. Wang Y, Tian Q, Xu X et al. Recombinant rabies virus expressing IFNa1 enhanced immune responses resulting in its attenuation and stronger immunogenicity. Virology 468-470C, 621-630 (2014
25. Masatani T, Ito N, Ito Y et al. Importance of rabies virus nucleoprotein in viral evasion of interferon response in the brain. Microbiol. Immunol. 57(7), 511-517 (2013
26. Zhang G, Wang H, Mahmood F, Fu ZF. Rabies virus glycoprotein is an important determinant for the induction of innate immune responses and the pathogenic mechanisms. Vet. Microbiol. 162(2-4), 601-613 (2013
27. Pollin R, Granzow H, Kollner B, Conzelmann KK, Finke S. Membrane and inclusion body targeting of Lyssavirus matrix proteins. Cell. Microbiol. 15(2), 200-212 (2013
28. Wiltzer L, Larrous F, Oksayan S et al. Conservation of a unique mechanism of immune evasion across the Lyssavirus genus. J. Virol. 86(18), 10194-10199 (2012
29. Albertini AA, Ruigrok RW, Blondel D. Rabies virus transcription and replication. Adv. Virus Res. 79, 1-22 (2011
30. Assenberg R, Delmas O, Ren J et al. Structure of the nucleoprotein binding domain of Mokola virus phosphoprotein. J. Virol. 84(2), 1089-1096 (2010
31. Schnell MJ, McGettigan JP, Wirblich C, Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nat. Rev. Microbiol. 8(1), 51-61 (2010
32. Masatani T, Ito N, Shimizu K et al. Rabies virus 603 nucleoprotein functions to evade activation of the RIG-I-mediated antiviral response. J. Virol. 84(8), 4002-4012 (2010
33. Faul EJ, Lyles DS, Schnell MJ. Interferon response and viral evasion by members of the family Rhabdoviridae. Viruses 1(3), 832-851 (2009
34. Menager P, Roux P, Megret F et al. Toll-like receptor 3 (TLR3) plays a major role in the formation of rabies virus Negri Bodies. PLoS Pathog. 5(2), e1000315 (2009
35. Castel G, Chteoui M, Caignard G et al. Peptides that mimic the amino-terminal end of the rabies virus phosphoprotein have antiviral activity. J. Virol. 83(20), 10808-10820 (2009
36. Ribeiro Ede A Jr, Leyrat C, Gerard FC et al. Binding of rabies virus polymerase cofactor to recombinant circular nucleoprotein-RNA complexes. J. Mol. Biol. 394(3), 558-575 (2009
37. Dodet B, Tejiokem MC, Aguemon AR, Bourhy H. Human rabies deaths in Africa: breaking the cycle of indifference. Int. Health 7(1), 4-6 (2015
38. Vora NM, Basavaraju SV, Feldman KA et al. Raccoon rabies virus variant transmission through solid organ transplantation. JAMA 310(4), 398-407 (2013
39. Hemachudha T, Ugolini G, Wacharapluesadee S, Sungkarat W, Shuangshoti S, Laothamatas J. Human rabies: neuropathogenesis, diagnosis, and management. Lancet Neurol. 12(5), 498-513 (2013
40. Jemberu WT, Molla W, Almaw G, Alemu S. Incidence of rabies in humans and domestic animals and people's awareness in North Gondar Zone, Ethiopia. PLoS Negl. Trop. Dis. 7(5), e2216 (2013
41. Suraweera W, Morris SK, Kumar R et al. Deaths from symptomatically identifiable furious rabies in India: a nationally representative mortality survey. PLoS Negl. Trop. Dis. 6(10), e1847 (2012
42. Simani S, Fayaz A, Rahimi P, Eslami N, Howeizi N, Biglari P. Six fatal cases of classical rabies virus without biting incidents, Iran 1990-2010. J. Clin. Virol. 54(3), 251-254 (2012
43. Feder HM Jr, Petersen BW, Robertson KL, Rupprecht CE. Rabies: still a uniformly fatal disease?. Historical occurrence, epidemiological trends, and paradigm shifts. Curr. Infect. Dis. Rep. 14(4), 408-422 (2012
44. Lankester F, Hampson K, Lembo T, Palmer G, Taylor L, Cleaveland S. Implementing Pasteur's vision for rabies elimination. Science 345, 1562-1564 (2014
45. Morters MK, McKinley TJ, Horton DL et al. Achieving population-level immunity to rabies in free-roaming dogs in Africa and Asia. PLoS Negl. Trop. Dis. 8(11), e3160 (2014
46. Lapiz SM, Miranda ME, Garcia RG et al. Implementation of an intersectoral program to eliminate human and canine rabies: the Bohol Rabies Prevention and Elimination Project. PLoS Negl. Trop. Dis. 6, e1891 (2012
47. Lembo T, Attlan M, Bourhy H et al. Renewed global partnerships and redesigned roadmaps for rabies prevention and control. Vet. Med. Int. doi: 10.4061/2011/923149 (2011). http://www.ncbi.nlm.nih.gov/pmc/articles
48. Meslin FX, Briggs DJ. Eliminating canine rabies, the principal source of human infection: what will it take?. Antiviral Res. 98, 291-296 (2013
49. Dyer JL, Yager P, Orciari L et al. Rabies surveillance in the United States during 2013. J. Am. Vet. Med. Assoc. 245(10), 1111-1123 (2014
50. Anderson A, Shwiff SA. The cost of canine rabies on four continents. Transbound Emerg. Dis. doi: 10.1111/tbed.12168 (2013
51. Townsend SE, Sumantra IP, Pudjiatmoko et al. Designing programs for eliminating canine rabies from islands: Bali, Indonesia as a case study. PLoS Negl. Trop. Dis. 7, e2372 (2013
52. Vigilato MA, Clavijo A, Knobl T et al. Progress towards eliminating canine rabies: policies and perspectives from Latin America and the Caribbean. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368, 20120143 (2013
53. National Association of State Public Health Veterinarians, Inc. Compendium of animal rabies prevention and control. MMWR Recomm. Rep. 60, 1-14 (2011
54. Johnson N, Arechiga-Ceballos N, Aguilar-Setien A. Vampire bat rabies: ecology, epidemiology and control. Viruses 6(5), 1911-1928 (2014
55. Ellison JA, Johnson SR, Kuzmina N et al. Multidisciplinary approach to epizootiology and pathogenesis of bat rabies viruses in the United States. Zoonoses Public Health 60(1), 46-57 (2013
56. Kuzmin IV, Shi M, Orciari La et al. Molecular inferences suggest multiple host shifts of rabies viruses from bats to mesocarnivores in Arizona during 2001-2009. PLoS Pathog. 8(6), e1002786 (2012
57. World Health Organization. Rabies vaccines: WHO position paper - recommendations. Vaccine 28(44), 7140-7142 (2010
58. Rupprecht CE, Briggs D, Brown CM et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 59(RR-2), 1-9 (2010
59. Laurent PE, Bourhy H, Fantino M, Alchas P, Mikszta JA. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine 28(36), 5850-5856 (2010
60. Sudarshan MK, Gangaboraiah B, Ravish HS, Narayana DH. Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route: results of a metaanalysis. Hum. Vaccine 6(7), 562-565 (2010
61. Kaur M, Garg R, Singh S, Bhatnagar R. Rabies vaccines: where do we stand, where are we heading?. Expert Rev. Vaccines 14(3), 369-381 (2015
62. Ren J, Yao L, Sun J, Gong Z. The abbreviated intramuscular schedules for rabies vaccination: Zagreb regimen. Clin. Vaccine Immunol. 22(1), 1-5 (2015
63. Malerczyk C, Vakil HB, Bender W. Rabies pre-exposure vaccination of children with purified chick embryo cell vaccine (PCECV). Hum. Vaccin. Immunother. 9(7), 1454-1459 (2013
64. Briggs DJ. The role of vaccination in rabies prevention. Curr. Opin. Virol. 2(3), 309-314 (2012
65. Liu Q, Ertl HC. Preventative childhood vaccination to rabies. Expert Opin. Biol. Ther. 12(8), 1067-1075 (2012
66. Khawplod P, Jaijaroensup W, Sawangvaree A, Prakongsri S, Wilde H. One clinic visit for pre-exposure rabies vaccination (a preliminary one year study). Vaccine 30(19), 2918-2920 (2012
67. Warrell MJ. Intradermal rabies vaccination: the evolution and future of pre- and post-exposure prophylaxis. Curr. Top. Microbiol. Immunol. 351, 139-157 (2012
68. Xiang ZQ, Greenberg L, Ertl HC, Rupprecht CE. Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology 450-451, 243-249 (2014
69. McGettigan JP. Experimental rabies vaccines for humans. Expert. Rev. Vaccines 9(10), 1177-1186 (2010
70. Warrell MJ. Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure. Travel Med. Infect. Dis. 10(1), 1-15 (2012
71. Both L, Banyard AC, van Dolleweerd C, Horton DL, Ma JK, Fooks AR. Passive immunity in the prevention of rabies. Lancet Infect. Dis. 12(5), 397-407 (2012
72. Wilde H, Wacharapluesadee S, Hemachudha T. Currently approved post-exposure rabies prophylaxis regimens. Travel Med. Infect. Dis. 10(3), 162-163 (2012
73. Sudarshan MK, Narayana DH, Madhusudana SN et al. Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India. Hum. Vaccin. Immunother. 8(8), 1077-1081 (2012
74. Wu X, Smith TG, Rupprecht CE. From brain passage to cell adaptation: the road of human rabies vaccine development. Expert Rev. Vaccines 10(11), 1597-1608 (2011
75. Shantavasinkul P, Tantawichien T, Wilde H et al. Postexposure rabies prophylaxis completed in 1 week: preliminary study. Clin. Infect. Dis. 50(1), 56-60 (2010
76. Shantavasinkul P, Tantawichien T, Wacharapluesadee S et al. Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations. Clin. Infect. Dis. 50(1), 77-79 (2010
77. Robertson K, Recuenco S, Niezgoda M, Garcia EJ, Rupprecht CE. Seroconversion following incomplete human rabies postexposure prophylaxis. Vaccine 28(39), 6523-6526 (2010
78. Mahendra BJ, Madhusudana SN, Sampath G et al. Immunogenicity, safety and tolerance of a purified duck embryo vaccine (PDEV, VAXIRAB) for rabies post-exposure prophylaxis: results of a multicentric study in India. Hum. Vaccin. 6(9), pii: 12216 (2010
79. Shantavasinkul P, Tantawichien T, Jaijaroensup W et al. A 4-site, single-visit intradermal postexposure prophylaxis regimen for previously vaccinated patients: experiences with >5000 patients. Clin. Infect. Dis. 51(9), 1070-1072 (2010
80. Quiambao BP, Dy-Tioco HZ, Dizon RM, Crisostomo ME, Teuwen DE. Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratoryconfirmed category III rabies exposure in the Philippines. Vaccine 27(51), 7162-7166 (2009
81. Rupprecht CE, Briggs D, Brown CM et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine 27(51), 7141-7148 (2009
82. Franka R, Wu X, Jackson FR et al. Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines. Vaccine 27(51), 7149-7155 (2009
83. van Dolleweerd CJ, Teh AY, Banyard AC et al. Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody. J. Infect. Dis. 210(2), 200-208 (2014
84. Nagarajan T, Marissen WE, Rupprecht CE. Monoclonal antibodies for the prevention of rabies: theory and clinical practice. Antibody Technol. J. 4, 1-12 (2014
85. Both L, van Dolleweerd C, Wright E et al. Production, characterization, and antigen specificity of recombinant 62-71-73, a candidate monoclonal antibody for rabies prophylaxis in humans. FASEB J. 27(5), 2055-2065 (2013
86. Gogtay N, Thatte U, Kshirsagar N et al. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine 30(50), 7315-7320 (2012
87. Muller T, Dietzschold B, Ertl H et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl. Trop. Dis. 3(11), e542 (2009
88. Gilbert AT, Petersen BW, Recuenco S et al. Evidence of rabies virus exposure among humans in the Peruvian Amazon. Am. J. Trop. Med. Hyg. 87(2), 206-215 (2012
89. Caicedo Y, Paez A, Kuzmin I et al. Virology, immunology and pathology of human rabies during treatment. Pediatr. Infect. Dis. J. (2014) (Epub ahead of print
90. Alandijany T, Kammouni W, Roy Chowdhury SK, Fernyhough P, Jackson AC. Mitochondrial dysfunction in rabies virus infection of neurons. J. Neurovirol. 19(6), 537-549 (2013
91. Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res. 99(1), 61-67 (2013
92. O'Sullivan A, Willoughby RE, Mishchuk D et al. Metabolomics of cerebrospinal fluid from humans treated for rabies. J. Proteome Res. 12(1), 481-490 (2013
93. Aramburo A, Willoughby RE, Bollen AW et al. Failure of the Milwaukee protocol in a child with rabies. Clin. Infect. Dis. 53(6), 572-574 (2011
94. Franka R, Rupprecht CE. Treatment of rabies in the 21st century: curing the incurable?. Future Microbiol. 6(10), 1135-1140 (2011
95. Hunter M, Johnson N, Hedderwick S et al. Immunovirological correlates in human rabies treated with therapeutic coma. J. Med. Virol. 82(7), 1255-1265 (2010
96. Reinke SN, Resch L, Maingat F et al. Metagenomic and metabolomic characterization of rabies encephalitis: new insights into the treatment of an ancient disease. J. Infect. Dis. 207(9), 1451-1456 (2013
97. Li J, Ertel A, Portocarrero C et al. Postexposure treatment with the liveattenuated rabies virus (RV) vaccine TriGAS triggers the clearance of wild-type RV from the central nervous system (CNS) through the rapid induction of genes relevant to adaptive immunity in CNS tissues. J. Virol. 86(6), 3200-3210 (2012
98. Jackson AC. Is minocycline useful for therapy of acute viral encephalitis?. Antiviral Res. 95(3), 242-244 (2012
99. Kammouni W, Hasan L, Saleh A, Wood H, Fernyhough P, Jackson AC. Role of nuclear factor-KB in oxidative stress associated with rabies virus infection of adult rat dorsal root ganglion neurons. J. Virol. 86(15), 8139-8146 (2012
100. Schutsky K, Portocarrero C, Hooper DC, Dietzschold B, Faber M. Limited brain metabolism changes differentiate between the progression and clearance of rabies virus. PLoS ONE 9(4), e87180 (2014
101. Oksayan S, Nikolic J, David CT, Blondel D, Jans DA, Moseley GW. Identification of a role for nucleolin in rabies virus infection. J. Virol. 89(3), 1939-1943 (2015
102. Appolinario CM, Jackson AC. Antiviral therapy for human rabies. Antivir. Ther. 20(1), 1-10 (2015
103. Mareeva T, Wanjalla C, Schnell MJ, Sykulev Y. A novel composite immunotoxin that suppresses rabies virus production by the infected cells. J. Immunol. Methods 353(1-2), 78-86 (2010
104. Lingappa UF, Wu X, Macieik A et al. Host-rabies virus protein-protein interactions as druggable antiviral targets. Proc. Natl Acad. Sci. USA 110(10), E861-E868 (2013
105. List of WHO prequalified vaccines. WHO (2015). http://www.who.int/immunization
106. Manongdo JF. FDA warns against fake rabies vaccine. Manila Bulletin (2013). http://www.mb.com.ph/fda-warns-against
107. Brown CS, Lee MS, Leung DW et al. In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J. Mol. Biol. 426(10), 2045-2058 (2014
108. Binning JM, Wang T, Luthra P et al. Development of RNA aptamers targeting Ebola virus VP35. Biochemistry 52(47), 8406-8419 (2013
109. The Humane Society of the United States. How to avoid a dog bite (2013). http://www.humanesociety.org/animals
110. Al Jazeera English. Lifelines: rabies. http://www.fao.org/livestock-environment
111. Han M, Kim CY, Rowland RR, Fang Y, Kim D, Yoo D. Biogenesis of non-structural protein 1 (nsp1) and nsp1-mediated type I interferon modulation in arteriviruses. Virology 458-459, 136-150 (2014
112. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. 104, 153-155 (2014
113. Singh B, Choi YJ, Park IK, Akaike T, Cho CS. Chemical modification of chitosan with pH-sensitive molecules and specific ligands for efficient DNA transfection and siRNA silencing. J. Nanosci. Nanotechnol. 14(1), 564-576 (2014
114. Gao S, Hein S, Dagnæs-Hansen F et al. Megalin-mediated specific uptake of chitosan/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing. Theranostics 4(10), 1039-1051 (2014
115. Pronker ES, Weenen TC, Commandeur HR, Osterhaus AD, Claassen HJ. The gold industry standard for risk and cost of drug and vaccine development revisited. Vaccine 29(35), 5846-5849 (2011
116. Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PLoS ONE 8(3), e57755 (2013
117. World Health Organization. Research Priorities for Zoonoses and Marginalized Infections. WHO, Geneva, Switzerland (2012
118. Warrell MJ, Warrell DA. Rabies: the clinical features, management and prevention of the classic zoonosis. Clin. Med. 15(1), 78-81 (2015
119. Chai Q, She R, Huang Y, Fu ZF. Expression of neuronal CXCL10 induced by rabies virus infection initiates infiltration of inflammatory cells, production of chemokines and cytokines, and enhancement of blood-brain barrier permeability. J. Virol. 89(1), 870-876 (2015
120. Lytle AG, Shen S, McGettigan JP. Lymph node but not intradermal injection site macrophages are critical for germinal center formation and antibody responses to rabies vaccination. J. Virol. 89(5), 2842-2848 (2015
121. Malerczyk C, Freuling C, Gniel D, Giesen A, Selhorst T, Müller T. Cross-neutralization of antibodies induced by vaccination with purified chick embryo cell vaccine (PCECV) against different Lyssavirus species. Hum. Vaccin. Immunother. 10(10), 2799-2804 (2014
122. Crowcroft NS, Thampi N. The prevention and management of rabies. BMJ 350, g7827 (2015
123. Tinsa F, Borgi A, Jahouat I, Boussetta K. Rabies encephalitis in a child: a failure of rabies post exposure prophylaxis?. BMJ Case Rep. doi: 10.1136/bcr-2014-206191 (2015
124. Jibat T, Hogeveen H, Mourits MC. Review on dog rabies vaccination coverage in Africa: a question of dog accessibility or cost recovery?. PLoS Negl. Trop. Dis. 9(2), e0003447 (2015
125. Müller T, Freuling CM, Wysocki P et al. Terrestrial rabies control in the European Union: historical achievements and challenges ahead. Vet. J. 203(1), 10-17 (2015